Vysis LSI IGH Dual Color, Break Apart Rearrangement Probe
For more information, contact Abbott.
For more information, contact Abbott.
| PRODUCT NAME | UNIT SIZE | ORDER NUMBER | GTIN |
|---|
Vysis LSI IGH Dual Color Break Apart Rearrangement Probe hybridizes to the band 14q32.3 (SpectrumGreen on the telomeric side and SpectrumOrange on the centromeric side of the IGH locus breakpoints). The hybridized probe fluoresces with moderate to bright intensity both in interphase nuclei and on metaphase chromosomes.
When hybridized to a normal nucleus, the LSI IGH Dual Color, Break Apart Rearrangement Probe produces a two orange/green (yellow) fusion (2F) signal pattern. As there is no probe targeted to the J or constant regions, a slight gap between the two differently colored probe signals may sometimes be observed in nuclei from normal cells. When the IGH Dual Color, Break Apart Translocation Probe is hybridized to a nucleus containing an IGH translocation, one orange, one green, and one orange/green fusion signal pattern is observed (1O1G1F). This signal pattern indicates that the genomic targets for the LSI IGHV and LSI IGH 3’ flanking probes have been physically separated as a result of the translocation. As V(D)J rearrangements may occur on either, or both, of the translocated and non- translocated IGH alleles, the green LSI IGHV probe signal intensity on either, or both, of the alleles may be diminished as a result of probe target deletion in some samples.
Normal Hybridization: LSI IGH Dual Color, Break Apart Rearrangement Probe hybridized to nuclei exhibiting the expected two fusion (2F) signal pattern.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.